Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independe...

Descripción completa

Detalles Bibliográficos
Autores principales: Smalley, Keiran SM, Fedorenko, Inna V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905349/
https://www.ncbi.nlm.nih.gov/pubmed/27308505
http://dx.doi.org/10.1080/23723556.2015.1008291